Seres Therapeutics, Inc. Investing Cash Flow
Seres Therapeutics, Inc. (MCRB) reported Investing Cash Flow of $14.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- Seres Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $14.00K.
- Seres Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $0.00.
- Seres Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $181.00K.
- Seres Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$8.00K, a 100.01% decline year-over-year.
- Seres Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$42.00K, a 100.03% decline from fiscal 2024.
- Seres Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $142.29M, a 1244.67% increase from fiscal 2023.
- Seres Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $10.58M, a 87.16% decline from fiscal 2022.
- Seres Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was $82.43M, a 28.62% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $14.00K 10-Q · filed 2026-08-05 | $195.00K derived: sum of 3 quarters · filed 2026-08-05 | $187.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $181.00K derived: sum of 2 quarters · filed 2026-05-05 | $173.00K derived: sum of 3 quarters · filed 2026-05-05 | -$8.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $173.00K derived: sum of 2 quarters · filed 2026-03-12 | -$8.00K derived: sum of 3 quarters · filed 2026-08-05 | -$42.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$189.00K derived: sum of 2 quarters · filed 2026-08-05 | -$223.00K 10-Q · filed 2025-11-05 | -$313.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$181.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$215.00K 10-Q · filed 2026-08-05 | -$305.00K derived: sum of 3 quarters · filed 2026-08-05 | $140.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$34.00K 10-Q · filed 2026-05-05 | -$124.00K derived: sum of 2 quarters · filed 2026-05-05 | $141.02M derived: sum of 3 quarters · filed 2026-05-05 | $142.32M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $141.05M derived: sum of 2 quarters · filed 2026-03-12 | $142.35M derived: sum of 3 quarters · filed 2026-03-12 | $142.29M 10-K · filed 2026-03-12 |
| 2024-09-30 | $141.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $142.44M derived: sum of 2 quarters · filed 2025-11-05 | $142.38M 10-Q · filed 2025-11-05 | $141.51M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.24M 10-Q · filed 2025-08-06 | $363.00K derived: sum of 3 quarters · filed 2026-03-12 | -$1.43M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | -$62.00K 10-Q · filed 2025-05-07 | -$939.00K derived: sum of 2 quarters · filed 2026-03-12 | -$2.74M derived: sum of 3 quarters · filed 2026-03-12 | $7.78M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | -$877.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.67M derived: sum of 2 quarters · filed 2026-03-12 | $7.84M derived: sum of 3 quarters · filed 2026-03-12 | $10.58M 10-K · filed 2026-03-12 |
| 2023-09-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $8.72M derived: sum of 2 quarters · filed 2024-11-13 | $11.46M 10-Q · filed 2024-11-13 | $17.39M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $10.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $13.26M 10-Q · filed 2024-08-13 | $19.18M derived: sum of 3 quarters · filed 2025-03-13 | $59.31M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $2.74M 10-Q · filed 2024-05-08 | $8.66M derived: sum of 2 quarters · filed 2025-03-13 | $48.80M derived: sum of 3 quarters · filed 2025-03-13 | $72.19M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $5.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $46.06M derived: sum of 2 quarters · filed 2025-03-13 | $69.46M derived: sum of 3 quarters · filed 2025-03-13 | $82.43M 10-K · filed 2025-03-13 |
| 2022-09-30 | $40.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $63.53M derived: sum of 2 quarters · filed 2023-11-02 | $76.50M 10-Q · filed 2023-11-02 | $89.69M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $23.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $36.37M 10-Q · filed 2023-08-08 | $49.56M derived: sum of 3 quarters · filed 2024-03-05 | $74.67M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $12.97M 10-Q · filed 2023-05-09 | $26.16M derived: sum of 2 quarters · filed 2024-03-05 | $51.27M derived: sum of 3 quarters · filed 2024-03-05 | $97.80M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $13.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $38.30M derived: sum of 2 quarters · filed 2024-03-05 | $84.83M derived: sum of 3 quarters · filed 2024-03-05 | $64.09M 10-K · filed 2024-03-05 |
| 2021-09-30 | $25.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $71.64M derived: sum of 2 quarters · filed 2022-11-02 | $50.90M 10-Q · filed 2022-11-02 | -$24.43M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $46.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $25.79M 10-Q · filed 2022-08-03 | -$49.55M derived: sum of 3 quarters · filed 2023-03-07 | -$160.19M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | -$20.74M 10-Q · filed 2022-05-04 | -$96.07M derived: sum of 2 quarters · filed 2023-03-07 | -$206.72M derived: sum of 3 quarters · filed 2023-03-07 | -$189.07M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | -$75.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$185.98M derived: sum of 2 quarters · filed 2023-03-07 | -$168.33M derived: sum of 3 quarters · filed 2023-03-07 | -$158.89M 10-K · filed 2023-03-07 |
| 2020-09-30 | -$110.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$92.99M derived: sum of 2 quarters · filed 2021-11-10 | -$83.56M 10-Q · filed 2021-11-10 | -$78.90M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $17.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $27.09M 10-Q · filed 2021-08-03 | $31.74M derived: sum of 3 quarters · filed 2022-03-01 | -$2.78M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $9.44M 10-Q · filed 2021-05-04 | $14.09M derived: sum of 2 quarters · filed 2022-03-01 | -$20.43M derived: sum of 3 quarters · filed 2022-03-01 | -$20.77M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$29.87M derived: sum of 2 quarters · filed 2022-03-01 | -$30.21M derived: sum of 3 quarters · filed 2022-03-01 | -$30.52M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$34.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$34.87M derived: sum of 2 quarters · filed 2020-11-09 | -$35.17M 10-Q · filed 2020-11-09 | -$17.77M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-06-30 | -$341.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | -$647.00K 10-Q · filed 2020-07-28 | $16.75M derived: sum of 3 quarters · filed 2021-03-02 | $37.29M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-03-31 | -$306.00K 10-Q · filed 2020-05-07 | $17.09M derived: sum of 2 quarters · filed 2021-03-02 | $37.63M derived: sum of 3 quarters · filed 2021-03-02 | $73.98M derived: sum of 4 quarters · filed 2021-03-02 |
| 2018-12-31 | $17.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $37.93M derived: sum of 2 quarters · filed 2021-03-02 | $74.28M derived: sum of 3 quarters · filed 2021-03-02 | $112.32M 10-K · filed 2021-03-02 |
| 2018-09-30 | $20.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $56.89M derived: sum of 2 quarters · filed 2019-11-05 | $94.92M 10-Q · filed 2019-11-05 | $104.22M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $36.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $74.38M 10-Q · filed 2019-08-06 | $83.68M derived: sum of 3 quarters · filed 2020-03-02 | $99.60M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $38.03M 10-Q · filed 2019-05-02 | $47.33M derived: sum of 2 quarters · filed 2020-03-02 | $63.25M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $25.22M derived: sum of 2 quarters · filed 2020-03-02 | $55.70M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $15.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $46.41M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $30.48M 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | -$65.59M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |